 TEL AVIV, Israel, Feb. 04, 2021 GLOBE NEWSWIRE -- InspireMD, Inc. InspireMD NYSE:NSPR, a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of 18 million or 20.7 million if the underwriters exercise their option to purchase additional securities prior to deducting underwriting discounts and estimated offering expenses payable by InspireMD. 